AIP and depressive symptom measurement: Whereas pharmacogenomic models primarily inform treatment selection and mitigation of adverse drug reactions after a depression diagnosis, our objective is pre-treatment risk stratification and mechanistic insight within hypothyroid cohorts—highlighting metabolic pathways (e.g., AIP, distance from CRI-I, ionized calcium, HOMA2 indices) that align with the depressive phenotype in HT patients.